INTELLIA THERAPEUTICS, INC. (NTLA) Spending and interest coverage
- R&D / revenue · 12 months: Value 582.68%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 114.10%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 582.68% | Research and development expense / revenue. Period ending 2026-06-30. $346.73M ÷ $59.51M × 100 ≈ 582.68% |
| Stock-based compensation / revenue · 12 months | 114.10% | Share-based compensation / revenue. Period ending 2026-06-30. $67.90M ÷ $59.51M × 100 ≈ 114.10% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 346.73M USD | Research and Development Expense |
| Revenue | 59.51M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 67.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -423.48M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $346.73M | $59.51M | $67.90M | $-423.48M | (m) | 582.68% | 114.10% | (m) | (m) |
| 2026-03-31 | $361.17M | $66.09M | $71.86M | $-420.71M | (m) | 546.47% | 108.72% | (m) | (m) |
| 2025-12-31 | $388.86M | $67.67M | $80.22M | $-440.99M | (m) | 574.63% | 118.54% | (m) | (m) |
| 2025-09-30 | $417.09M | $57.53M | $103.10M | $-478.73M | (m) | 725.01% | 179.21% | (m) | (m) |
| 2025-06-30 | $445.72M | $52.86M | $123.11M | $-512.02M | (m) | 843.25% | 232.92% | (m) | (m) |
| 2025-03-31 | $462.89M | $45.57M | $141.94M | $-541.07M | (m) | 1015.80% | 311.48% | (m) | (m) |
| 2024-12-31 | $466.31M | $57.88M | $154.27M | $-534.26M | (m) | 805.69% | 266.55% | (m) | (m) |
| 2024-09-30 | $458.42M | $43.09M | $149.70M | $-537.71M | (m) | 1063.95% | 347.44% | (m) | (m) |
| 2024-06-30 | $448.73M | $45.97M | $145.43M | $-524.04M | (m) | 976.20% | 316.38% | (m) | (m) |
| 2024-03-31 | $449.80M | $52.60M | $140.97M | $-517.34M | (m) | 855.07% | 267.99% | (m) | (m) |
| 2023-12-31 | $435.07M | $36.27M | $134.05M | $-515.29M | (m) | 1199.36% | 369.54% | (m) | (m) |
| 2023-09-30 | $426.12M | $51.77M | $123.63M | $-485.49M | (m) | 823.19% | 238.84% | (m) | (m) |
| 2023-06-30 | $409.08M | $53.04M | $113.50M | $-459.91M | (m) | 771.28% | 213.99% | (m) | (m) |
| 2023-03-31 | $384.00M | $53.48M | $100.16M | $-425.88M | (m) | 718.09% | 187.31% | (m) | (m) |
| 2022-12-31 | $419.98M | $52.12M | $91.40M | $-458.16M | (m) | 805.78% | 175.36% | (m) | (m) |
| 2022-09-30 | $391.11M | $51.40M | $81.33M | $-428.49M | (m) | 760.88% | 158.23% | (m) | (m) |
| 2022-06-30 | $354.94M | $45.34M | $71.53M | $-394.95M | (m) | 782.84% | 157.76% | (m) | (m) |
| 2022-03-31 | $323.63M | $37.86M | $59.08M | $-365.67M | (m) | 854.80% | 156.04% | (m) | (m) |
| 2021-12-31 | $229.81M | $33.05M | $47.01M | $-267.85M | (m) | 695.27% | 142.22% | (m) | (m) |
| 2021-09-30 | $196.88M | $26.79M | $38.03M | $-229.83M | (m) | 734.78% | 141.93% | (m) | (m) |
| 2021-06-30 | $176.15M | $41.81M | $28.02M | $-185.94M | (m) | 421.30% | 67.02% | (m) | (m) |
| 2021-03-31 | $155.03M | $51.52M | $22.17M | $-149.96M | (m) | 300.90% | 43.03% | (m) | (m) |
| 2020-12-31 | $150.41M | $57.99M | $19.90M | $-136.58M | (m) | 259.35% | 34.32% | (m) | (m) |
| 2020-09-30 | $143.91M | $62.34M | $17.34M | $-123.95M | (m) | 230.86% | 27.81% | (m) | (m) |
| 2020-06-30 | $131.66M | $50.73M | $15.02M | $-121.18M | (m) | 259.54% | 29.60% | (m) | (m) |
| 2020-03-31 | $119.35M | $45.59M | $14.66M | $-115.61M | (m) | 261.82% | 32.15% | (m) | (m) |
| 2019-12-31 | $108.41M | $43.10M | $15.09M | $-106.37M | (m) | 251.52% | 35.01% | (m) | (m) |
| 2019-09-30 | $96.60M | $40.05M | $15.66M | $-97.34M | (m) | 241.22% | 39.10% | (m) | (m) |
| 2019-06-30 | $92.32M | $36.84M | $17.03M | $-96.11M | (m) | 250.61% | 46.24% | (m) | (m) |
| 2019-03-31 | $90.33M | $33.40M | $17.53M | $-92.25M | (m) | 270.47% | 52.49% | (m) | (m) |
| 2018-12-31 | $89.11M | $30.43M | $17.05M | $-90.87M | (m) | 292.81% | 56.01% | (m) | (m) |
| 2018-09-30 | $90.37M | (m) | $20.06M | $-94.84M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $84.61M | (m) | $18.85M | $-86.61M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $76.71M | (m) | $16.80M | $-79.04M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $67.65M | (m) | $15.32M | $-69.56M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $57.81M | (m) | $10.74M | $-55.66M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $48.19M | (m) | $9.55M | $-47.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $40.05M | (m) | $8.53M | $-38.41M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $31.84M | (m) | $6.71M | $-32.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $11.17M | (m) | $1.31M | $-13.41M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |